AtriCure, Inc. (ATRC) Stock

AtriCure, Inc. is a pioneering medical technology company that specializes in the development, manufacturing, and global distribution of advanced devices for surgical cardiac tissue ablation and nerve systems. Operating across the United States, Europe, Asia, and worldwide, the company provides a comprehensive range of innovative products designed to enhance surgical precision and efficacy.

Among its flagship offerings are the Isolator Synergy Clamps, disposable radio frequency products renowned for their precision in cardiac ablation procedures. AtriCure also offers multifunctional pens and linear ablation devices like the MAX Pen, which integrates multiple functionalities for evaluating cardiac arrhythmias, temporary pacing, sensing, stimulation, and tissue ablation in a single device. The Coolrail device further extends capabilities by enabling longer linear ablation lines.

The company's portfolio includes the cryoICE Cryoablation System for creating varied lengths of linear ablations, and the EPi-Sense Guided Coagulation System, a disposable device used to treat atrial fibrillation. AtriCure's innovative solutions also encompass the AtriClip System, facilitating precise tissue closure with an implantable device, and the LARIAT System, a suture-based solution for soft-tissue closure adaptable to various anatomical shapes.

Founded in 2000 and headquartered in Mason, Ohio, AtriCure, Inc. markets its products through a network of independent distributors and direct sales teams. With a commitment to advancing surgical outcomes in cardiac procedures, the company continues to lead in innovation, providing essential tools for cardiac surgeons worldwide.